Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.94Last Year’s EPS
-0.93Same Quarter Last Year
Strong Buy
Based on 14 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -7.80%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in regulatory milestones, clinical trial advancements, and financial stability. However, it also noted challenges such as revenue decline, increased net loss, and high anticipated cash burn. Overall, the positive developments in drug approvals and clinical trials suggest optimism for future growth.Company Guidance
During the 2025 conference call, Crinetics Pharmaceuticals provided guidance for the upcoming year, highlighting several key metrics and milestones. The company announced its first NDA filing for paltusotine, targeting a PDUFA date of September 25, 2025, and plans to launch the drug for acromegaly treatment by the end of the year. Additionally, Crinetics is preparing to file an MAA with the EMA within the first half of 2025. The company is also advancing atumelnant into Phase III trials for CAH and Cushing's disease, highlighting promising Phase II data with rapid and substantial reductions in key biomarkers. Financially, Crinetics ended 2024 with $1.4 billion in cash and investments, projecting a 2025 cash burn of $340-$380 million, facilitating the initiation of four late-stage trials. The company's strategic growth into Europe is supported by a new hub in Zug, Switzerland, and an expansion into Germany, with a focus on building a robust commercial infrastructure.NDA Acceptance for Paltusotine
The FDA accepted the NDA for paltusotine for acromegaly with a PDUFA date of September 25, 2025. This is Crinetics' first NDA filing.
Positive Clinical Data for Paltusotine and Atumelnant
Paltusotine showed rapid, sustained reductions in carcinoid symptoms in Phase II, while Atumelnant demonstrated significant biomarker and symptom improvements in CAH and Cushing's disease trials.
Strong Financial Position
Crinetics ended 2024 with approximately $1.4 billion in cash and investments, expected to fund operations into 2029.
Expansion into European Market
Crinetics is preparing for EMA filing for paltusotine in acromegaly and has established a hub in Switzerland to expand into the European market.
IND Submissions for 2025
Crinetics plans to submit 4 INDs in 2025, including for the SST2-targeting NDC 9682 for tumors, PTH antagonist for hyperparathyroidism, TSH antagonist for hyperthyroidism, and SST3 agonist for ADPKD.
---
CRNX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CRNX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $33.21 | $35.78 | +7.74% |
| Nov 12, 2024 | $58.78 | $58.92 | +0.24% |
| Aug 08, 2024 | $50.74 | $47.64 | -6.11% |
| May 09, 2024 | $49.42 | $48.00 | -2.87% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Crinetics Pharmaceuticals (CRNX) report earnings?
Crinetics Pharmaceuticals (CRNX) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Crinetics Pharmaceuticals (CRNX) earnings time?
Crinetics Pharmaceuticals (CRNX) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CRNX EPS forecast?
CRNX EPS forecast for the fiscal quarter 2025 (Q1) is -0.94.
---